Astria Therapeutics, Inc. (ATXS) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-01-23

Key Insights

The reported transactions involve the cancellation of Sunil Agarwal's stock options in Astria Therapeutics as a result of the merger between Astria and BioCryst Pharmaceuticals, where Astria became a wholly-owned subsidiary of BioCryst.
Agarwal held two stock options, one with an exercise price of $11.40 and the other with an exercise price of $5.79, both of which were canceled in exchange for cash payments based on the $13.00 per share merger consideration.
The reported transactions indicate that Agarwal, who served as a director of Astria, is no longer affiliated with the company following the completion of the merger.

Want the newest filings?

This analysis covers the filing from 2026-01-23. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-01-23

The reporting person Kenneth Bate, a director of Astria Therapeutics, Inc. (ATXS), sold multiple stock options on January 23, 2026 as a result of the company's merger with BioCryst Pharmaceuticals, Inc.
The stock options sold were a mix of in-the-money and out-of-the-money options, with the out-of-the-money options canceled for no consideration.
The sale of the in-the-money options for cash suggests the reporting person is cashing out their position, potentially indicating a change in their outlook on the company's future prospects.

Filed: 2026-01-23

This Form 4 filing discloses that Joanne Beck, a director at Astria Therapeutics, Inc. (ATXS), had various stock options canceled as a result of the company's merger with BioCryst Pharmaceuticals, Inc. on January 23, 2026.
The cancellation of Beck's stock options appears to be part of the merger agreement, where options with exercise prices below $13 were canceled in exchange for cash payments, while options above $13 were canceled without compensation.
This filing provides insight into the financial terms of the merger transaction and the impact on Astria Therapeutics' executive compensation arrangements.

Filed: 2026-01-23

The reporting person, Fred Callori, is a director of Astria Therapeutics, Inc. (ATXS) and has reported changes in his beneficial ownership of the company's securities.
Pursuant to a merger agreement, Astria Therapeutics was acquired by BioCryst Pharmaceuticals, Inc. on January 23, 2026. As a result, Callori's stock options were either cashed out or canceled.
The reporting person held various stock options with different exercise prices, ranging from $3 to $12.24 per share, which were all canceled or cashed out as part of the merger transaction.

Filed: 2026-01-23

The reporting person, Noah Clauser, who is the Chief Financial Officer of Astria Therapeutics, Inc. (ATXS), exercised 55,000 and 262,500 stock options on January 23, 2026.
The stock option exercises were part of a merger agreement between Astria Therapeutics and BioCryst Pharmaceuticals, where Astria Therapeutics became a wholly-owned subsidiary of BioCryst.
The reporting person's 'Out-of-the-Money' options were canceled for no consideration as part of the merger agreement.

Filed: 2026-01-23

The reporting person, Hugh Cole, exercised several stock options in Astria Therapeutics, Inc. (ATXS) on January 23, 2026, shortly before the company was acquired by BioCryst Pharmaceuticals, Inc.
The stock options that were in-the-money (exercise price less than $13) were canceled in exchange for a cash payment, while the out-of-the-money options were canceled for no consideration.
This filing provides insight into the insider trading activity and the terms of the acquisition, which could be valuable information for investors.

Filed: 2026-01-23

Astria Therapeutics' Chief Legal Officer, Benjamin Harshbarger, exercised stock options as part of a merger agreement with BioCryst Pharmaceuticals, Inc.
Harshbarger's options were either 'In-the-Money' (exercise price < $13) and were canceled in exchange for cash payment, or 'Out-of-the-Money' (exercise price >= $13) and were canceled with no consideration.
The merger transaction appears to have provided liquidity for Harshbarger's equity holdings in Astria Therapeutics.

Filed: 2026-01-23

The reporting person, Michael Kishbauch, is a director of Astria Therapeutics, Inc. (ATXS) and has made several changes to his stock option holdings.
Kishbauch's options with exercise prices below $13 were canceled in exchange for a cash payment as part of Astria's merger with BioCryst Pharmaceuticals, while his higher-priced options were canceled for no consideration.
The option transactions appear to be related to Astria's acquisition by BioCryst, which may provide insight into the financial terms and strategic rationale for the deal.

Filed: 2026-01-23

The reporting person, Andrew Komjathy, is the Chief Commercial Officer of Astria Therapeutics, Inc. and has disposed of a total of 100 shares of the company's common stock.
Komjathy also held stock options for 55,000 and 225,000 shares of Astria's common stock, which were canceled in exchange for cash payments as part of the company's merger with BioCryst Pharmaceuticals.
Some of the disposed shares were held indirectly by Komjathy's minor child and adult child, with the reporting person disclaiming beneficial ownership over those shares.

Filed: 2026-01-23

The filing indicates that Astria Therapeutics, Inc. (ATXS) was acquired by BioCryst Pharmaceuticals, Inc. through a merger transaction on January 23, 2026.
The filing discloses the treatment of Astria's outstanding stock options in the merger, with in-the-money options being canceled in exchange for cash payments and out-of-the-money options being canceled for no consideration.
The reporting person, Anthony Gregg Lapointe, appears to be a director of Astria Therapeutics and the filing provides details on his holdings of Astria's stock options that were impacted by the merger.

Filed: 2026-01-23

The filing indicates that Astria Therapeutics, Inc. (ATXS) was acquired by BioCryst Pharmaceuticals, Inc. in a merger transaction on January 23, 2026.
The reporting person, Andrea Matthews, was the Chief Business Officer of Astria Therapeutics and held various stock options which were canceled and cashed out as part of the merger agreement.
The filing provides details on the terms of the merger, including the treatment of in-the-money and out-of-the-money stock options held by the reporting person.

Filed: 2026-01-23

Astria Therapeutics, Inc. (ATXS) has been acquired by BioCryst Pharmaceuticals, Inc. through a merger transaction, with ATXS becoming a wholly-owned subsidiary of BioCryst.
The CEO and President, Jill C. Milne, has disposed of 4,377 shares of ATXS common stock as part of the merger agreement, receiving a combination of BioCryst shares and cash consideration.
The merger transaction resulted in the cancelation of Milne's outstanding stock options, with the in-the-money options being canceled in exchange for cash payments based on the merger price.

Filed: 2026-01-23

The filing indicates that Astria Therapeutics, Inc. (ATXS) has been acquired by BioCryst Pharmaceuticals, Inc. (BCRX) through a merger agreement.
The reporting person, Christopher Morabito, who is the Chief Medical Officer of Astria Therapeutics, had stock options that became fully vested and were canceled in exchange for cash payments as part of the merger.
The filing also notes that Morabito's out-of-the-money stock options were canceled for no consideration, which is exempt from Section 16 reporting requirements.

Filed: 2026-01-23

Astria Therapeutics, Inc. (ATXS) has been acquired by BioCryst Pharmaceuticals, Inc. (BCRX) through a merger transaction. This will likely provide liquidity for Astria shareholders.
The filing shows that company director Jonathan Violin disposed of his entire 263,321 share stake in Astria as part of the merger. This could signal the completion of the acquisition.
The merger terms indicate that Astria shareholders will receive 0.59 shares of BioCryst stock and $8.55 in cash for each Astria share held, suggesting a significant premium for Astria investors.

Other reports for Astria Therapeutics, Inc.

Current Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.